1. Mechanisms of resistance to EGFR tyrosine kinase inhibitors
   Lihua Huang et al, 2015, Acta Pharmaceutica Sinica B CrossRef
2. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds
   Ge-Ping Qu et al, 2021, BMC Pulmonary Medicine CrossRef
3. Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D‐Aromatic‐Boron‐Rich‐Cluster into the 4‐Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment
   Marcos Couto et al, 2018, Chemistry – A European Journal CrossRef
4. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells
   Yaling Zhang et al, 2018, European Journal of Medicinal Chemistry CrossRef
5. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
   Surya K. Tripathi et al, 2020, Medicinal Research Reviews CrossRef
6. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer
   Christy W.S. Tong et al, 2017, Cancer Letters CrossRef
7. Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
   Junnan Li et al, 2020, Cancers CrossRef